This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: July 3, 2008
Last updated: December 4, 2014
Last verified: December 2014
Study to compare of two contrast agents in imaging brain lesions.

Condition Intervention Phase
Neoplastic CNS Lesions Drug: Gadovist® (Gadobutrol, BAY86-4875) Drug: Dotarem Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Diagnostic
Official Title: Contrast-enhanced MRI Examination of Cerebral Neoplastic Enhancing Lesions: Comparison of Diagnostic Efficacy of Gd-DOTA 0.5M and Gadobutrol 1.0 M at 0.1 mmol/kg Body Weight: Intraindividual Comparison Clinical Study.

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • The primary analysis will be the comparison of the enhancements characteristics of Gadobutrol and Gd-TOTA on a lesion per lesion basis. [ Time Frame: October 2007 to November 2008 ]

Enrollment: 166
Study Start Date: March 2008
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Gadovist® (Gadobutrol, BAY86-4875)
0,1 mmol/kg of body weight in the vein, single administration
Active Comparator: Arm 2 Drug: Dotarem
0,1 mmol/kg of body weight in the vein, single administration


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Known neoplastic CNS lesions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00764387

Andria, Bari, Italy, 70031
Catania, Italy, 95126
Chieti, Italy, 66013
Messina, Italy, 98122
Milano, Italy, 20132
Napoli, Italy, 80131
Novara, Italy, 28100
Roma, Italy, 00133
Roma, Italy, 00168
Siena, Italy, 53100
Trieste, Italy, 34149
Verona, Italy, 37136
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT00764387     History of Changes
Other Study ID Numbers: 91780
2007-005693-31 ( EudraCT Number )
312021 ( Other Identifier: Company Internal )
Study First Received: July 3, 2008
Last Updated: December 4, 2014

Keywords provided by Bayer:
Neoplastic CNS lesions
Contrast enhanced MRI
Comparison processed this record on September 21, 2017